Invivo Therapeutics Holdings Corp Company Profile (OTCMKTS:NVIV)

Analyst Ratings

Consensus Ratings for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) (?)
Ratings Breakdown: 2 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.33)
Consensus Price Target: $20.42

Analysts' Ratings History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Show:
DateFirmActionRatingPrice TargetActions
7/21/2016Ladenburg ThalmannInitiated CoverageBuy$23.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2016Raymond James Financial Inc.Initiated CoverageStrong-Buy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/6/2016($0.26)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015($0.20)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.05)($0.64)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015($0.04)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014($0.05)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014($0.06)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.08)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014($0.08)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/9/2014Francis ReynoldsMajor ShareholderSell50,000$1.20$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Francis ReynoldsMajor ShareholderSell37,500$1.87$70,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2014Francis ReynoldsMajor ShareholderSell37,500$1.82$68,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2014Francis ReynoldsMajor ShareholderSell50,000$1.52$76,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2014Francis ReynoldsMajor ShareholderSell50,000$1.57$78,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Francis ReynoldsMajor ShareholderSell37,500$1.63$61,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/9/2014Francis ReynoldsMajor ShareholderSell37,500$1.60$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Francis ReynoldsMajor ShareholderSell25,000$1.71$42,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Francis ReynoldsMajor ShareholderSell37,500$1.71$64,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2014Francis ReynoldsMajor ShareholderSell47,900$1.80$86,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Francis ReynoldsMajor ShareholderSell39,600$2.15$85,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Francis ReynoldsMajor ShareholderSell37,500$2.44$91,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.33$87,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.49$93,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Francis ReynoldsMajor ShareholderSell37,500$2.28$85,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/21/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Francis ReynoldsMajor ShareholderSell25,000$2.24$56,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.25$84,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.21$82,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/31/2014Francis ReynoldsMajor ShareholderSell25,000$2.17$54,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/24/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Francis ReynoldsMajor ShareholderSell37,500$2.36$88,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Francis ReynoldsMajor ShareholderSell48,000$2.41$115,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2014Francis ReynoldsMajor ShareholderSell36,000$2.28$82,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2013Francis ReynoldsMajor ShareholderSell36,000$2.25$81,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013Francis ReynoldsMajor ShareholderSell36,000$1.99$71,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.96$47,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.80$43,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Francis ReynoldsMajor ShareholderSell36,000$1.75$63,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.59$38,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.92$46,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Francis ReynoldsMajor ShareholderSell36,000$1.95$70,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2013Francis ReynoldsMajor ShareholderSell36,000$1.14$41,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013Francis ReynoldsMajor ShareholderSell24,000$1.11$26,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2013Francis ReynoldsMajor ShareholderSell36,000$1.16$41,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Francis ReynoldsMajor ShareholderSell24,000$1.16$27,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Francis ReynoldsMajor ShareholderSell36,000$1.23$44,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Francis ReynoldsMajor ShareholderSell24,000$1.35$32,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.40$33,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/18/2013Francis ReynoldsMajor ShareholderSell24,000$1.45$34,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2013Francis ReynoldsMajor ShareholderSell36,000$1.49$53,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.51$36,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2013Francis ReynoldsMajor ShareholderSell36,000$1.41$50,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.41$33,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.37$32,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.43$51,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.50$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.72$41,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.61$38,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.36$32,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Sean F MoranCFOBuy20,000$1.02$20,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Francis ReynoldsMajor ShareholderSell9,200$1.55$14,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Sean F MoranCFOBuy40,000$1.30$52,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2013Francis ReynoldsMajor ShareholderSell12,600$3.24$40,824.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/23/2013Francis ReynoldsMajor ShareholderSell21,300$4.07$86,691.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013Francis ReynoldsCEOSell36,000$4.12$148,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Francis ReynoldsCEOSell24,000$4.24$101,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Francis ReynoldsCEOSell36,000$4.34$156,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013Francis ReynoldsCEOSell24,000$4.42$106,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2013Francis ReynoldsCEOSell36,000$4.46$160,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013Francis ReynoldsCEOSell24,000$4.57$109,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Francis ReynoldsCEOSell24,000$5.11$122,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013Francis ReynoldsCEOSell24,000$5.29$126,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2013Francis ReynoldsCEOSell36,000$5.72$205,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/19/2013Francis ReynoldsCEOSell24,000$5.27$126,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2013Francis ReynoldsCEOSell36,000$5.12$184,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Francis ReynoldsCEOSell24,000$4.43$106,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2013Francis ReynoldsCEOSell36,000$3.97$142,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013Francis ReynoldsCEOSell12,000$4.00$48,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Francis ReynoldsCEOSell36,000$4.08$146,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013Francis ReynoldsCEOSell24,000$4.22$101,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2013Francis ReynoldsCEOSell36,000$3.87$139,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Francis ReynoldsCEOSell24,000$3.78$90,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Francis ReynoldsCEOSell36,000$3.89$140,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Francis ReynoldsCEOSell24,000$3.84$92,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Francis ReynoldsCEOSell12,750$4.34$55,335.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013Francis ReynoldsCEOSell8,500$4.02$34,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Francis ReynoldsCEOSell12,750$3.75$47,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Robert LangerMajor ShareholderSell7,500$3.73$27,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Francis ReynoldsCEOSell8,500$3.32$28,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Robert LangerMajor ShareholderSell7,500$3.31$24,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Francis ReynoldsCEOSell8,500$3.13$26,605.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Robert LangerMajor ShareholderSell7,500$2.97$22,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2013Francis ReynoldsCEOSell8,500$2.95$25,075.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Robert LangerMajor ShareholderSell7,500$2.88$21,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Francis ReynoldsCEOSell12,750$2.88$36,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Francis ReynoldsCEOSell8,500$2.87$24,395.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Robert LangerMajor ShareholderSell7,500$2.85$21,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Francis ReynoldsCEOSell12,750$2.89$36,847.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Francis ReynoldsCEOSell8,500$2.92$24,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2013Francis ReynoldsCEOSell8,500$3.16$26,860.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2013Francis ReynoldsCEOSell12,750$2.03$25,882.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
DateHeadline
07/22/16 05:26 PMHow Analysts Feel About Invivo Therapeutics Holdings Corp After Today's Huge Increase? - Consumer Eagle
07/22/16 05:26 PMLadenburg Thalmann Initiates Coverage on Invivo Therapeutics Holdings Corp to Buy - TheFounders Daily
07/22/16 08:30 AMInVivo Therapeutics : to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
07/21/16 05:51 PMInVivo Therapeutics : Receives Investigational Testing Authorization from Health Canada
07/20/16 06:18 PMTop Stories: Sprint Corporation (NYSE:S), InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), AT&T, Inc. (NYSE:T ... - KC Register
07/18/16 05:40 PMInVivo Therapeutics Announces Ben Taub Hospital/Baylor College of Medicine as New Site for INSPIRE Study - Business Wire (press release)
07/18/16 05:40 PMTrading Spotlight - Shares on the Rise in Session: InVivo Therapeutics Holdings Corp. (:NVIV) - TGP
07/18/16 07:00 AMInVivo Therapeutics Announces Ben Taub Hospital/Baylor College of Medicine as New Site for INSPIRE Study - [Business Wire] - InVivo Therapeutics Holdings Corp. today announced that the Ben Taub Hospital in Houston, TX has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.
07/17/16 09:46 AMShares Moving Down on the Week: InVivo Therapeutics Holdings Corp. (:NVIV) - Engelwood Daily
07/17/16 09:46 AMInvivo Therapeutics Holdings Cor (NASDAQ:NVIV) Shorted Shares Decreased By 15.03% - Consumer Eagle
07/15/16 10:27 AMInvivo Therapeutics (NVIV) Announces Investigational Testing Authorization from Health Canada - StreetInsider.com
07/15/16 10:27 AMRaymond James Initiates Coverage on Invivo Therapeutics Holdings Corp to Strong Buy - Trade Calls
07/15/16 10:27 AMInVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study - Business Wire (press release)
07/14/16 07:38 AMInVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study - [at noodls] - Leading Spinal Cord Researcher Dr. Michael Fehlings and Toronto Western Hospital Join INSPIRE CAMBRIDGE, Mass. (July 14, 2016) - InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received ...
07/13/16 05:54 PMBRIEF-Invivo says FDA approved enrollment of additional patients to allow for 20 evaluable patients in inspire study
07/13/16 05:54 PMForm 8-K INVIVO THERAPEUTICS HOLD For: Jul 12
07/13/16 08:30 AMInVivo Therapeutics Receives Investigational Testing Authorization from Health Canada - Business Wire (press release)
07/13/16 07:33 AMInVivo Therapeutics Receives Investigational Testing Authorization from Health Canada - [at noodls] - CAMBRIDGE, Mass. (July 13, 2016) - InVivo Therapeutics Holdings Corp. (NVIV) today announced that Health Canada has approved the company's Investigational Testing Authorization application to commence ...
07/12/16 05:49 PMInVivo Therapeutics Announces Update on the INSPIRE Study and FDA Approval of Expansion of the Study to 20 ... - Business Wire (press release)
07/12/16 05:49 PMInVivo Therapeutics Holdings Corp. Realized Volatility Hits Elevated Level - CML News
07/12/16 09:54 AMStock on the Rise for the Quarter: InVivo Therapeutics Holdings Corp. (:NVIV) - Engelwood Daily
07/12/16 09:54 AMInvivo Therapeutics (NVIV) Announces Additional Enrollments, Update of INSPIRE Study of the Neuro-Spinal Scaffold - StreetInsider.com
07/12/16 07:23 AMInVivo Therapeutics Announces Update on the INSPIRE Study and FDA Approval of Expansion of the Study to 20 Evaluable Patients - [at noodls] - CAMBRIDGE, Mass. (July 12, 2016) - InVivo Therapeutics Holdings Corp. (NVIV) today provided an update on the INSPIRE study of the Neuro-Spinal Scaffold™. ... This is an abstract of the original noodl. ...
07/08/16 08:30 AMInVivo Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - Yahoo Finance
07/08/16 07:31 AMInVivo Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [at noodls] - CAMBRIDGE, Mass. (July 8, 2016) - InVivo Therapeutics Holdings Corp. (NVIV) today announced that Christopher McNulty, Senior Vice President of Business Development and Investor Relations, is scheduled ...
07/07/16 05:38 AMCoverage initiated on InVivo Therapeutics by Raymond James -
06/25/16 09:16 AMInvivo Therapeutics Holdings Cor (NASDAQ:NVIV) Shorts Decreased by 8.06% After Short Covering - Engelwood Daily
06/23/16 08:16 AMInVivo Therapeutics Holdings Corp. (NasdaqGM:NVIV) Stock Momentum Hits Weakness - CML News
06/23/16 08:16 AMInVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society - Business Wire (press release)
06/23/16 07:19 AMInVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society - [at noodls] - CAMBRIDGE, Mass. (Jun 23, 2016) - InVivo Therapeutics Holdings Corp. (NVIV) today announced that Richard Layer, Ph.D., InVivo's Senior Director of Research, will be giving a poster presentation at the ...
06/22/16 10:17 AMInVivo Therapeutics Announces Publication in Neurosurgery of Case Report Detailing First Neuro-Spinal Scaffold ... - Business Wire (press release)
06/22/16 07:19 AMInVivo Therapeutics Announces Publication in Neurosurgery of Case Report Detailing First Neuro-Spinal Scaffold™ Implantation - [at noodls] - CAMBRIDGE, Mass. (Jun 22, 2016) - InVivo Therapeutics Holdings Corp. (NVIV) today announced the publication of a case report in the journal Neurosurgery detailing the first clinical Neuro-Spinal Scaffold ...
06/09/16 05:54 PMBRIEF-Invivo Therapeutics files for mixed shelf of up to $150 mln - SEC filing - Reuters
06/08/16 05:58 PMBRIEF-Invivo Therapeutics says Christina Morrison appointed as chairwoman of audit committee - Reuters
06/08/16 05:58 PMINVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Financial Condition Compared to S&P 500 - CML News
06/08/16 05:58 PMInVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors - Business Wire (press release)
06/08/16 07:28 AMInVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors - [at noodls] - CAMBRIDGE, Mass. (Jun 8, 2016) - InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Christina Morrison to its Board of Directors effective immediately. Most recently, Ms. Morrison ...
06/06/16 01:27 PMInvivo Therapeutics Holdings Corp. :NVIV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
05/26/16 10:11 AMIs Buying Stock Like Invivo Therapeutics Holdings Corp After Such Increase Winning Strategy? - Wall Street Hints and News - Is Buying Stock Like Invivo Therapeutics Holdings Corp After Such Increase Winning Strategy?Wall Street Hints and NewsThe stock of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) is a huge mover today! The stock increased 5.09% or $0.33 during the last trading session, hitting $6.81. About 323,765 shares traded hands. Invivo Therapeutics Holdings Corp ...
05/26/16 10:11 AMInVivo Therapeutics Featured on CBS Radio Affiliate - Business Wire (press release) - InVivo Therapeutics Featured on CBS Radio AffiliateBusiness Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a WBZ NewsRadio 1030 (CBS – Boston) interview with New England Business reporter Jeff Brown. Mr. Brown has been ...and more »
05/26/16 07:17 AMInVivo Therapeutics Featured on CBS Radio Affiliate - [at noodls] - - Industry Veteran Jeff Brown Interviews CEO and Chairman Mark Perrin on WBZ NewsRadio 1030 in Boston - CAMBRIDGE, Mass. (May 26, 2016) - InVivo Therapeutics Holdings Corp. (NVIV) today announced that ...
03/14/16 01:53 PMHot Alert: Anavex Life Sciences Corp. (NASDAQ:AVXL), InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), SAP SE ... - KC Register - Hot Alert: Anavex Life Sciences Corp. (NASDAQ:AVXL), InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), SAP SE ...KC RegisterInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced that Thomas Jefferson University Hospital has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of theNeuro-Spinal Scaffold™ for Safety and Neurologic ...and more »
02/29/16 08:26 AMInVivo Therapeutics Reports Objective Performance Criterion for INSPIRE Study - InVivo Therapeutics Holdings Corp. (NVIV) today announced it has received approval of a significant protocol amendment from the U.S. Food and Drug Administration (FDA). The amended protocol establishes the Objective Performance Criterion (OPC) for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. An OPC is a measure of study success used in clinical studies designed to demonstrate safety and probable benefit in support of a Humanitarian Device Exemption (HDE) approval. The OPC for The INSPIRE Study is defined as 25% or more of the patients in the study demonstrating an improvement of ...Full story available on Benzinga.com
02/26/16 11:22 AMBetter Buy: Organovo Holdings Inc vs. United Therapeutics Corporation - Motley Fool - Motley FoolBetter Buy: Organovo Holdings Inc vs. United Therapeutics CorporationMotley FoolThat said, I'll give a cautious nod to Organovo, as its 3-D bioprinter gives the company -- for now -- a virtual monopoly on in vivo, bioprinted cells. While $100 million itself is less than United Therapeutics pulls in during a quarter, Organovo is ...and more »
02/26/16 11:22 AMInVivo Therapeutics Announces Symposium and Oral Platform Presentation at Spine Summit 2016 - Business Wire (press release) - InVivo Therapeutics Announces Symposium and Oral Platform Presentation at Spine Summit 2016Business Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be holding its first-ever symposium at the 2016 Spine Summit meeting on Thursday, March 17, 2016 in Orlando, FL. The meeting is ...Invivo Therapeutics Holdings Cor (NASDAQ:NVIV) Short Interest Decreased By 1.26%Stock Callerall 4 news articles »
02/04/16 01:09 PMInVivo Therapeutics Reports University of California San Diego Medical Center as New Site for INSPIRE Study - Investing News Network (press release) (registration) (blog) - InVivo Therapeutics Reports University of California San Diego Medical Center as New Site for INSPIRE StudyInvesting News Network (press release) (registration) (blog)InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced that University of California (UC), San Diego Medical Center has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety ...
02/04/16 01:09 PMIt Seems Invivo Therapeutics Holdings Corp Will Go Down. Just Reaches 52-Week Low - WallStreet.org - It Seems Invivo Therapeutics Holdings Corp Will Go Down. Just Reaches 52-Week LowWallStreet.orgThe stock of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) hit a new 52-week low and has $3.58 target or 11.00% below today's $4.02 share price. The 8 months bearish chart indicates high risk for the $118.46M company. The 1-year low was reported ...InVivo Therapeutics Announces University of California San Diego Medical Center as New Site for INSPIRE StudyPharmiWeb.com (press release)all 2 news articles »
02/03/16 12:43 PMInVivo Therapeutics Announces University of California San Diego Medical Center as New Site for INSPIRE Study - Business Wire (press release) - InVivo Therapeutics Announces University of California San Diego Medical Center as New Site for INSPIRE StudyBusiness Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that University of California (UC), San Diego Medical Center has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of ...InVivo Therapeutics Reports University of California San Diego Medical Center as New Site for INSPIRE StudyInvesting News Network (press release) (registration) (blog)all 2 news articles »
01/30/16 12:20 PMInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Short Interest Update - The Daily Rover - InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Short Interest UpdateThe Daily RoverInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) stated gains of 96,540 shares or 3.1% in the short interest. The short interest registered from 3,137,649 on December 31,2015 to 3,234,189 on January 15,2016. In terms of floated shares, the shorted ...
01/27/16 07:04 PMInVivo Therapeutics Holdings Enters Oversold Territory (NVIV) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of InVivo Therapeutics Holdings Corp (NVIV) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $4.28 per share.

Social

About Invivo Therapeutics Holdings Corp

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: NVIV
  • CUSIP:
Key Metrics:
  • Previous Close: $6.57
  • 50 Day Moving Average: $6.29
  • 200 Day Moving Average: $6.04
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $210.91M
  • Current Year EPS Consensus Estimate: $-0.91 EPS
  • Next Year EPS Consensus Estimate: $-0.94 EPS
Additional Links:
Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) Chart for Saturday, July, 23, 2016